Portal de Periódicos da CAPES

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

2016; Elsevier BV; Volume: 128; Issue: 14 Linguagem: Inglês

10.1182/blood-2016-07-726729

1528-0020

Torben Plesner, Hendrik‐Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson,

Peptidase Inhibition and Analysis

Key Points Daratumumab plus lenalidomide/dexamethasone elicited an overall response rate of 81% (63% very good partial response or better). Adverse events were manageable and in accord with the individual toxicity profiles of daratumumab and lenalidomide/dexamethasone.